Your browser doesn't support javascript.
loading
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning.
Sugita, Junichi; Kawashima, Naomi; Fujisaki, Tomoaki; Kakihana, Kazuhiko; Ota, Shuichi; Matsuo, Keitaro; Miyamoto, Toshihiro; Akashi, Koichi; Taniguchi, Shuichi; Harada, Mine; Teshima, Takanori.
Afiliação
  • Sugita J; Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • Kawashima N; Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
  • Fujisaki T; Department of Hematology, Matsuyama Red Cross Hospital, Matsuyama, Japan.
  • Kakihana K; Hematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo, Japan.
  • Ota S; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Matsuo K; Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan.
  • Miyamoto T; Department of Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan.
  • Akashi K; Department of Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan.
  • Taniguchi S; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
  • Harada M; Karatsu Higashimatsuura Medical Center, Karatsu, Japan.
  • Teshima T; Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. Electronic address: teshima@med.hokudai.ac.jp.
Biol Blood Marrow Transplant ; 21(9): 1646-52, 2015 Sep.
Article em En | MEDLINE | ID: mdl-26093044
Allogeneic hematopoietic stem cell transplantation (allo-SCT) using post-transplant cyclophosphamide (PTCy) is increasingly performed. We conducted a multicenter phase II study to evaluate the safety and efficacy of PTCy-based HLA-haploidentical peripheral blood stem cell transplantation (PTCy-haploPBSCT) after busulfan-containing reduced-intensity conditioning. Thirty-one patients were enrolled; 61% patients were not in remission and 42% patients had a history of prior allo-SCT. Neutrophil engraftment was achieved in 87% patients with a median of 19 days. The cumulative incidence of grades II to IV and III to IV acute graft-versus-host disease (GVHD) and chronic GVHD at 1 year were 23%, 3%, and 15%, respectively. No patients developed severe chronic GVHD. Day 100 nonrelapse mortality (NRM) rate was 19.4%. Overall survival, relapse, and disease-free survival rates were 45%, 45%, and 34%, respectively, at 1 year. Subgroup analysis showed that patients who had a history of prior allo-SCT had lower engraftment, higher NRM, and lower overall survival than those not receiving a prior allo-SCT. Our results suggest that PTCy-haploPBSCT after busulfan-containing reduced-intensity conditioning achieved low incidences of acute and chronic GVHD and NRM and stable donor engraftment and low NRM, particularly in patients without a history of prior allo-SCT.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bussulfano / Neoplasias Hematológicas / Condicionamento Pré-Transplante / Ciclofosfamida / Transplante de Células-Tronco de Sangue Periférico / Antígenos HLA Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Japão País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bussulfano / Neoplasias Hematológicas / Condicionamento Pré-Transplante / Ciclofosfamida / Transplante de Células-Tronco de Sangue Periférico / Antígenos HLA Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Biol Blood Marrow Transplant Assunto da revista: HEMATOLOGIA / TRANSPLANTE Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Japão País de publicação: Estados Unidos